{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:07:07Z","timestamp":1763424427610,"version":"3.45.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s41030-025-00311-4","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:52:01Z","timestamp":1757130721000},"page":"587-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Adherence and Persistence of Upfront Therapy in Patients with Pulmonary Arterial Hypertension in the United States"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0183-4704","authenticated-orcid":false,"given":"Teresa","family":"De Marco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1331-9462","authenticated-orcid":false,"given":"Carly J.","family":"Paoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5017-1834","authenticated-orcid":false,"given":"Nicole S.","family":"Croteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0297-7902","authenticated-orcid":false,"given":"Harrison W.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"311_CR1","doi-asserted-by":"crossref","unstructured":"Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327(14):1379\u201391 (Erratum in: JAMA. 2022;328(9):892).","DOI":"10.1001\/jama.2022.4402"},{"issue":"1","key":"311_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020977300","volume":"11","author":"L Leber","year":"2021","unstructured":"Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11(1): 2045894020977300.","journal-title":"Pulm Circ"},{"issue":"1","key":"311_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1378\/chest.10-1166","volume":"140","author":"LM Brown","year":"2011","unstructured":"Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011;140(1):19\u201326.","journal-title":"Chest"},{"issue":"1","key":"311_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert M, Kovacs G, Hoeper MM, ESC\/ERS Scientific Document Group, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1): 2200879.","journal-title":"Eur Respir J"},{"issue":"4","key":"311_CR5","doi-asserted-by":"publisher","first-page":"2401325","DOI":"10.1183\/13993003.01325-2024","volume":"64","author":"KM Chin","year":"2024","unstructured":"Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401325.","journal-title":"Eur Respir J"},{"issue":"1","key":"311_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40256-022-00553-6","volume":"23","author":"S Qadus","year":"2023","unstructured":"Qadus S, Naser AY, Ofori-Asenso R, Ademi Z, Al Awawdeh S, Liew D. Adherence and discontinuation of disease-specific therapies for pulmonary arterial hypertension: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2023;23(1):19\u201333.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"173","key":"311_CR7","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0006-2024","volume":"33","author":"A Le Bozec","year":"2024","unstructured":"Le Bozec A, Korb-Savoldelli V, Boiteau C, et al. Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review. Eur Respir Rev. 2024;33(173): 240006.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"311_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019880086","volume":"10","author":"RP Frantz","year":"2020","unstructured":"Frantz RP, Hill JW, Lickert CA, et al. Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors. Pulm Circ. 2020;10(1): 2045894019880086.","journal-title":"Pulm Circ"},{"issue":"1","key":"311_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s41030-019-00106-4","volume":"6","author":"S Studer","year":"2020","unstructured":"Studer S, Hull M, Pruett J, Elliott C, Tsang Y, Drake W. Retrospective database analysis of treatment patterns among patients with pulmonary arterial hypertension. Pulm Ther. 2020;6(1):79\u201392.","journal-title":"Pulm Ther"},{"issue":"4","key":"311_CR10","doi-asserted-by":"publisher","first-page":"2401180","DOI":"10.1183\/13993003.01180-2024","volume":"64","author":"IR Preston","year":"2024","unstructured":"Preston IR, Howard LS, Langleben D, et al. Management of pulmonary hypertension in special conditions. Eur Respir J. 2024;64(4):2401180.","journal-title":"Eur Respir J"},{"issue":"4","key":"311_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12441","volume":"14","author":"OA Shlobin","year":"2024","unstructured":"Shlobin OA, Bruce G, Gomez Rendon G, et al. Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis. Pulm Circ. 2024;14(4): e12441.","journal-title":"Pulm Circ"},{"key":"311_CR12","doi-asserted-by":"crossref","unstructured":"Dean BB, Saundankar V, Stafkey-Mailey D, et al. Medication adherence and healthcare costs among patients with pulmonary arterial hypertension treated with oral prostacyclins: a retrospective cohort study. Drugs Real World Outcomes. 2020;7(3):229\u201339 (Erratum in: Drugs Real World Outcomes. 2020;7(3):241\u20132).","DOI":"10.1007\/s40801-020-00183-x"},{"issue":"2","key":"311_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.36469\/9812","volume":"5","author":"G Ruiz","year":"2018","unstructured":"Ruiz G, Yeaw J, Lickert CA, et al. Using real world evidence to describe pulmonary arterial hypertension treatment patterns, healthcare resource utilization, and costs associated with PDE-5 inhibitor monotherapy. J Health Econ Outcomes Res. 2018;5(2):206\u201319.","journal-title":"J Health Econ Outcomes Res"},{"issue":"8 Suppl 3","key":"311_CR14","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/MLR.0b013e31829b1d2a","volume":"51","author":"MA Raebel","year":"2013","unstructured":"Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11-21.","journal-title":"Med Care"},{"issue":"10","key":"311_CR15","first-page":"1073","volume":"25","author":"SL Canfield","year":"2019","unstructured":"Canfield SL, Zuckerman A, Anguiano RH, et al. Navigating the wild west of medication adherence reporting in specialty pharmacy. J Manag Care Spec Pharm. 2019;25(10):1073\u20137.","journal-title":"J Manag Care Spec Pharm"},{"key":"311_CR16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","volume":"9","author":"PC Baumgartner","year":"2018","unstructured":"Baumgartner PC, Haynes RB, Hersberger KE, Arnet I. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;9:1290.","journal-title":"Front Pharmacol"},{"issue":"12","key":"311_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/pds.4334","volume":"26","author":"WF Gellad","year":"2017","unstructured":"Gellad WF, Thorpe CT, Steiner JF, Voils CI. The myths of medication adherence. Pharmacoepidemiol Drug Saf. 2017;26(12):1437\u201341.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"311_CR18","unstructured":"Tracleer\u00ae (bosentan) tablets, for oral use. US prescribing information. Johnson & Johnson; 2024."},{"key":"311_CR19","unstructured":"Revatio\u00ae (sildenafil) tablets, for oral use. US prescribing information. Viatris Specialty LLC; 2024."},{"key":"311_CR20","unstructured":"Adcirca\u00ae (tadalafil) tablets, for oral use. US prescribing information. Eli Lilly and Company; 2020."},{"key":"311_CR21","unstructured":"Letairis\u00ae (ambrisentan) tablets, for oral use. US prescribing information. Gilead Sciences, Inc.; 2025."},{"key":"311_CR22","unstructured":"Opsumit\u00ae (macitentan) tablets, for oral use. US prescribing information. Johnson & Johnson; 2025."},{"issue":"22","key":"311_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026620","volume":"11","author":"EM Schikowski","year":"2022","unstructured":"Schikowski EM, Swabe G, Chan SY, Magnani JW. Association between copayment and adherence to medications for pulmonary arterial hypertension. J Am Heart Assoc. 2022;11(22): e026620.","journal-title":"J Am Heart Assoc"},{"key":"311_CR24","doi-asserted-by":"publisher","first-page":"1030693","DOI":"10.3389\/fphar.2022.1030693","volume":"13","author":"CY Tsai","year":"2023","unstructured":"Tsai CY, Shen CW, Lai HL, Chen CY. Adherence and treatment patterns of disease-specific drugs among patients with pulmonary arterial hypertension: a nationwide, new-user cohort study. Front Pharmacol. 2023;13:1030693.","journal-title":"Front Pharmacol"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00311-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:04:28Z","timestamp":1763424268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00311-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00311-4","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"type":"print","value":"2364-1754"},{"type":"electronic","value":"2364-1746"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Teresa De Marco has received research grants from CareDx and Acceleron; has received consultancy fees from Aerovate, Boston Scientific, Atara, Keros, Merck, Natera, Pulnovo, Tectonic, and United Therapeutics; has participated on advisory boards or data safety monitoring boards for Kamada, Merck, Keros Therapeutics, Tectonic, and BIAL; has received honoraria for a Simply Speaking PAH CME lecture; has received support for meeting attendance from CareDx, Atara, Kamada, and United Therapeutics; and has served on an endpoint adjudication committee for Johnson & Johnson. Carly J. Paoli is an employee and stockholder of Johnson & Johnson. Nicole S. Croteau and Fei Tang were employees of Cytel at the time of this study. Cytel has received consultancy fees from Johnson & Johnson for the conduct of this study. Harrison W. Farber has received speaking honoraria from Bayer and scientific advisory board fees from Acceleron (Merck), Actelion (Janssen), Altavant, Aerami, Aerovate, Pulmovant, and United Therapeutics, and is the Adjudicator for Keros.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As the study was retrospective and used only deidentified aggregated patient data, it was exempt from ethical or institutional review board review\/approval. The Komodo Health Research Database is compliant with the Health Insurance Portability and Accountability Act of 1996. The data were used under license from Komodo.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}